Celularity Inc. Class A Common Stock CELU
i
Market dataready · fetched 2026-11-03T20:15:10.638Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T19:59:42.105038713Z
FundamentalsSEC EDGAR · ready · as of 2026-06-30 · fetched 2026-11-03T20:15:09.974167+00:00
Celularity Inc. Class A Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 0.67 | 704.5% | 68.8% | |||
| 25Δ | 0.77 | 641.3% | 58.2% | |||
| 30Δ | 7.26 | 751.3% | 798.1% | 0.88 | 578.1% | 47.6% |
| 35Δ | 6.38 | 770.2% | 702.5% | 0.99 | 514.9% | 37.0% |
| 40Δ | 5.50 | 789.1% | 606.8% | 1.36 | 508.9% | 33.4% |
| 45Δ | 4.69 | 800.0% | 514.8% | 1.73 | 506.9% | 30.2% |
| 50Δ | 3.97 | 800.0% | 427.5% | 2.11 | 504.8% | 27.0% |
| 55Δ | 3.25 | 800.0% | 340.2% | 2.49 | 502.8% | 23.9% |
| 60Δ | 2.87 | 500.7% | 20.7% | |||
| 65Δ | 3.25 | 498.7% | 17.5% | |||
| 70Δ | 0.77 | 333.5% | 27.5% | 3.63 | 496.6% | 14.4% |
| 75Δ | 0.69 | 322.5% | 21.0% | 4.01 | 494.5% | 11.2% |
| 80Δ | 0.61 | 311.4% | 14.5% | 4.39 | 492.5% | 8.0% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.67
- IV
- 704.5%
- B/E move
- 68.8%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.77
- IV
- 641.3%
- B/E move
- 58.2%
30Δ
- Pseudo strike
- 7.26
- IV
- 751.3%
- B/E move
- 798.1%
- Pseudo strike
- 0.88
- IV
- 578.1%
- B/E move
- 47.6%
35Δ
- Pseudo strike
- 6.38
- IV
- 770.2%
- B/E move
- 702.5%
- Pseudo strike
- 0.99
- IV
- 514.9%
- B/E move
- 37.0%
40Δ
- Pseudo strike
- 5.50
- IV
- 789.1%
- B/E move
- 606.8%
- Pseudo strike
- 1.36
- IV
- 508.9%
- B/E move
- 33.4%
45Δ
- Pseudo strike
- 4.69
- IV
- 800.0%
- B/E move
- 514.8%
- Pseudo strike
- 1.73
- IV
- 506.9%
- B/E move
- 30.2%
50Δ
- Pseudo strike
- 3.97
- IV
- 800.0%
- B/E move
- 427.5%
- Pseudo strike
- 2.11
- IV
- 504.8%
- B/E move
- 27.0%
55Δ
- Pseudo strike
- 3.25
- IV
- 800.0%
- B/E move
- 340.2%
- Pseudo strike
- 2.49
- IV
- 502.8%
- B/E move
- 23.9%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.87
- IV
- 500.7%
- B/E move
- 20.7%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.25
- IV
- 498.7%
- B/E move
- 17.5%
70Δ
- Pseudo strike
- 0.77
- IV
- 333.5%
- B/E move
- 27.5%
- Pseudo strike
- 3.63
- IV
- 496.6%
- B/E move
- 14.4%
75Δ
- Pseudo strike
- 0.69
- IV
- 322.5%
- B/E move
- 21.0%
- Pseudo strike
- 4.01
- IV
- 494.5%
- B/E move
- 11.2%
80Δ
- Pseudo strike
- 0.61
- IV
- 311.4%
- B/E move
- 14.5%
- Pseudo strike
- 4.39
- IV
- 492.5%
- B/E move
- 8.0%
Options history
No recorded observations
Biotechnology
CGEM
Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients in the United…
More →CGON
CG Oncology, Inc. is a clinical-stage biotechnology firm focused on developing groundbreaking cancer therapies, particularly through its lead product, CG0070, an oncolytic virus…
More →CHRS
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. The company is headquartered in…
More →CING
Cingulate Inc., a clinical-stage biopharmaceutical company, is focused on developing candidate products for the treatment of neurobiological and central nervous system disorders.…
More →CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.…
More →CLYM
Description unavailable
More →